ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.

BMC Med · 2022 · PMC9069852 · PMID 35509036

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

marginally significantP = 0.081so close (0.05 < p ≤ 0.1)

In the SH&WH cohort, the interactions between ctDNA-adjusted bTMB and treatment were marginally significant for OS (interaction P = 0.081) and PFS (interaction P = 0.062).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.